BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.
加利福尼亞州帕洛阿爾託，2025年1月8日（環球新聞通訊社）-- BridgeBio Pharma, Inc.（納斯達克：BBIO）（「BridgeBio」或「公司」），是一家專注於遺傳疾病的新型生物製藥公司，今天宣佈其聯合創始人兼首席執行官Neil Kumar博士將於1月13日星期一上午7:30在加州舊金山舉行的第43屆摩根大通醫療健康會議上進行演講。
To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
要訪問BridgeBio演示的直播網絡研討會，請訪問BridgeBio網站投資者部分中的「活動與演示」頁面。事件結束後，網絡研討會的回放將在BridgeBio網站上提供30天。
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
關於BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.（BridgeBio）是一家新型生物製藥公司，成立的目的是發現、創造、測試和提供變革性藥物，以治療遭受遺傳疾病的患者。BridgeBio的開發項目管道從早期科學到愛文思控股臨牀試驗不等。BridgeBio成立於2015年，其團隊由經驗豐富的藥物發現者、開發者和創新者組成，致力於將遺傳醫學的進步儘快應用於幫助患者。有關更多信息，請訪問bridgebio.com，並在LinkedIn、Twitter和Facebook上關注我們。
BridgeBio Media Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
BridgeBio媒體聯繫方式：
維克拉姆·巴利
contact@bridgebio.com
(650)-789-8220
譯文內容由第三人軟體翻譯。
